KLH

BIOLOGICAL8 trials

Conditions

Brain TumorsGastric CancerGiant Cell GlioblastomaGlioblastomaGlioblastoma With Oligodendroglial ComponentGliosarcomaHealthy VolunteersImmunoproliferative Disorder

Phase 1

S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer

TerminatedNCT00023634

SWOG Cancer Research NetworkBrain Tumors, Gastric Cancer, Ovarian Cancer +1

Start: 2001-06-30End: 2008-11-30Updated: 2015-03-06

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

CompletedNCT00923910

National Cancer Institute (NCI)Leukemia, Acute Lymphocytic (ALL), Leukemia, Acute Myelogenous (AML), Leukemia, Chronic Myelogenous (CML) +2

Start: 2008-02-22End: 2016-11-15Updated: 2017-04-12

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects

CompletedNCT04079062

Ono Pharmaceutical Co. LtdHealthy Volunteers

Start: 2019-09-12End: 2021-05-25Updated: 2024-05-03

Phase 2

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

CompletedNCT00001145

National Institute of Allergy and Infectious Diseases (NIAID)Immunoproliferative Disorder

Start: 1999-10-31End: 2003-10-31Target: 5Updated: 2008-03-04

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

CompletedNCT01498328

Celldex TherapeuticsGiant Cell Glioblastoma, Glioblastoma, Glioblastoma With Oligodendroglial Component +4

Start: 2011-12-31End: 2016-05-17Updated: 2020-02-17

Phase 3

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

CompletedNCT01480479

Celldex TherapeuticsGiant Cell Glioblastoma, Glioblastoma, Glioblastoma With Oligodendroglial Component +2

Start: 2011-11-30End: 2016-11-30Updated: 2018-01-16

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

CompletedNCT02545868

Hoffmann-La RocheMultiple Sclerosis, Relapsing-Remitting

Start: 2015-10-27End: 2021-09-21Updated: 2024-03-26

Phase 4

A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)

CompletedNCT02576145

Hoffmann-La RocheKidney Transplantation

Start: 2003-04-30End: 2006-01-31Updated: 2016-01-13

2025-01-3012 citations

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022.

2023-01-0112 citations

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.

2020-08-01147 citations

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

Neurology2020-07-30330 citations

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.

2020-02-07134 citations

Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis (S36.002)

Neurology2018-04-1026 citations

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

2017-08-23820 citations

ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma (retracted)

CNS Oncology2015-12-1525 citations

ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.

Journal of Clinical Oncology2015-05-2073 citations

Development of algorithms for a quantitative real time-PCR assay to determine EGFRvIII status in glioblastoma patients from rindopepimut clinical trials.

Journal of Clinical Oncology2015-05-20

KLH

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Phase 4

Related Papers